TenNor Therapeutics Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 38

Employees

  • Latest Deal Type
  • Series E

  • Latest Deal Amount
  • $42.3M

  • Investors
  • 14

TenNor Therapeutics General Information

Description

Developer of innovative drugs for diseases associated with bacterial infections and bacterial dysbiosis. The company's platform offers a multi-targeting product development portfolio for treating diseases associated with gastrointestinal tract infection and dysbiosis, medical device infections, and bacterial vaginosis, enabling users to get new drugs for the treatment of various diseases with unmet needs.

Contact Information

Website
www.tennorx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 701, Building B7, Biopharmaceutical Industrial Park
  • No. 218 Xinghu Street
  • Suzhou, Jiangsu 215123
  • China
+86 0512
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Room 701, Building B7, Biopharmaceutical Industrial Park
  • No. 218 Xinghu Street
  • Suzhou, Jiangsu 215123
  • China
+86 0512

TenNor Therapeutics Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

TenNor Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series E) 24-Sep-2024 $42.3M Completed Generating Revenue
6. Later Stage VC (Series D1) 05-Jan-2023 Completed Clinical Trials - General
5. Later Stage VC (Series D) 25-Feb-2022 Completed Clinical Trials - General
4. Later Stage VC (Series C) 30-Jun-2020 Completed Clinical Trials - General
3. Later Stage VC (Series C) 18-May-2016 Completed Clinical Trials - General
2. Early Stage VC (Series B) 21-Nov-2013 $7M $7M Completed Startup
1. Early Stage VC (Series A) 22-May-2013 Completed Startup
To view TenNor Therapeutics’s complete valuation and funding history, request access »

TenNor Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of innovative drugs for diseases associated with bacterial infections and bacterial dysbiosis. The company's p
Drug Discovery
Suzhou, China
38 As of 2023

Barcelona, Spain
 

Shanghai, China
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

TenNor Therapeutics Competitors (16)

One of TenNor Therapeutics’s 16 competitors is Ona Therapeutics, a Venture Capital-Backed company based in Barcelona, Spain.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ona Therapeutics Venture Capital-Backed Barcelona, Spain
StemiRNA Therapeutics Biotech Venture Capital-Backed Shanghai, China
Loxo Oncology Formerly VC-backed Stamford, CT
Cardurion Venture Capital-Backed Burlington, MA
Genentech Formerly VC-backed South San Francisco, CA
You’re viewing 5 of 16 competitors. Get the full list »

TenNor Therapeutics Patents

TenNor Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240082229-A1 Methods for preventing or treating h. pylori infection Active 18-Aug-2022
US-12005050-B2 Methods for preventing or treating h. pylori infection Active 18-Aug-2022
US-20240000755-A1 Pharmaceutical composition comprising sulbactam and avibactam, and application thereof Pending 27-Aug-2021
JP-2022548067-A Penam derivatives for treating bacterial infections Active 11-Sep-2019
US-20210070774-A1 Penam derivatives for treating bacterial infections Active 11-Sep-2019 A61P31/04
To view TenNor Therapeutics’s complete patent history, request access »

TenNor Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

TenNor Therapeutics Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
AMR Action Fund Impact Investing Minority
Zhongshan Finance Investment Venture Capital Minority
Broad Resources PE/Buyout Minority
Bison Capital Financial Holdings Venture Capital Minority
Galaxy Holdings Growth/Expansion Minority
You’re viewing 5 of 14 investors. Get the full list »

TenNor Therapeutics FAQs

  • When was TenNor Therapeutics founded?

    TenNor Therapeutics was founded in 2013.

  • Where is TenNor Therapeutics headquartered?

    TenNor Therapeutics is headquartered in Suzhou, China.

  • What is the size of TenNor Therapeutics?

    TenNor Therapeutics has 38 total employees.

  • What industry is TenNor Therapeutics in?

    TenNor Therapeutics’s primary industry is Drug Discovery.

  • Is TenNor Therapeutics a private or public company?

    TenNor Therapeutics is a Private company.

  • What is TenNor Therapeutics’s current revenue?

    The current revenue for TenNor Therapeutics is .

  • How much funding has TenNor Therapeutics raised over time?

    TenNor Therapeutics has raised $118M.

  • Who are TenNor Therapeutics’s investors?

    AMR Action Fund, Zhongshan Finance Investment, Broad Resources, Bison Capital Financial Holdings, and Galaxy Holdings are 5 of 14 investors who have invested in TenNor Therapeutics.

  • Who are TenNor Therapeutics’s competitors?

    Ona Therapeutics, StemiRNA Therapeutics Biotech, Loxo Oncology, Cardurion, and Genentech are some of the 16 competitors of TenNor Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »